Limits...
ECT2 amplification and overexpression as a new prognostic biomarker for early-stage lung adenocarcinoma.

Murata Y, Minami Y, Iwakawa R, Yokota J, Usui S, Tsuta K, Shiraishi K, Sakashita S, Satomi K, Iijima T, Noguchi M - Cancer Sci. (2014)

Bottom Line: Array-comparative genomic hybridization indicated frequent amplification at chromosome 3q26.These results were verified using another set of early-stage adenocarcinomas resected at another hospital.Abnormality of the ECT2 gene occurs at a relatively early stage of lung adenocarcinogenesis and would be applicable as a new biomarker for prognostication of patients with lung adenocarcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.

Show MeSH

Related in: MedlinePlus

(a) Amplification of seven selected genes was examined using 15 adenocarcinomas in situ (AIS; Type A or B; blue dot) and 17 early-invasive adenocarcinomas (eIAD; Type D or E; red dot) by quantitative real-time genomic PCR. The ECT2, EIF5A2, PIK3CA, and TNFSF10 genes showed no amplification in AIS (blue arrows). (b) Quantitative real-time genomic PCR was carried out for ECT2, EIF5A2, PIK3CA, and TNFSF10 in 83 lung adenocarcinomas. Values in parentheses indicate the number of cases tested for each type of carcinoma. Seven cases (8%) showed amplification of ECT2, seven (8%) for EIF5A2, nine (11%) for PIK3CA, and eight (10%) for TNFSF10. IAD, invasive adenocarcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317802&req=5

fig01: (a) Amplification of seven selected genes was examined using 15 adenocarcinomas in situ (AIS; Type A or B; blue dot) and 17 early-invasive adenocarcinomas (eIAD; Type D or E; red dot) by quantitative real-time genomic PCR. The ECT2, EIF5A2, PIK3CA, and TNFSF10 genes showed no amplification in AIS (blue arrows). (b) Quantitative real-time genomic PCR was carried out for ECT2, EIF5A2, PIK3CA, and TNFSF10 in 83 lung adenocarcinomas. Values in parentheses indicate the number of cases tested for each type of carcinoma. Seven cases (8%) showed amplification of ECT2, seven (8%) for EIF5A2, nine (11%) for PIK3CA, and eight (10%) for TNFSF10. IAD, invasive adenocarcinoma.

Mentions: The seven selected gene amplifications were examined using 15 AIS (Type A or B) and 17 early-invasive adenocarcinomas (Type D or E) by qPCR (Fig. 1a). All seven genes showed amplification in early-invasive adenocarcinomas, confirming the results of Cancer Array-800. However, several cases of AIS showed amplification of EVI1, SKIL, and MUC4. In contrast, ECT2, EIF5A2, PIK3CA, and TNFSF10 showed no amplification in AIS. Additionally, 51 advanced lung adenocarcinomas, giving a total of 83 adenocarcinomas, were also examined by qPCR. Altogether, seven cases (8%) were amplified at ECT2, seven (8%) at EIF5A2, nine (11%) at PIK3CA, and eight (10%) at TNFSF10 (Fig. 1b).


ECT2 amplification and overexpression as a new prognostic biomarker for early-stage lung adenocarcinoma.

Murata Y, Minami Y, Iwakawa R, Yokota J, Usui S, Tsuta K, Shiraishi K, Sakashita S, Satomi K, Iijima T, Noguchi M - Cancer Sci. (2014)

(a) Amplification of seven selected genes was examined using 15 adenocarcinomas in situ (AIS; Type A or B; blue dot) and 17 early-invasive adenocarcinomas (eIAD; Type D or E; red dot) by quantitative real-time genomic PCR. The ECT2, EIF5A2, PIK3CA, and TNFSF10 genes showed no amplification in AIS (blue arrows). (b) Quantitative real-time genomic PCR was carried out for ECT2, EIF5A2, PIK3CA, and TNFSF10 in 83 lung adenocarcinomas. Values in parentheses indicate the number of cases tested for each type of carcinoma. Seven cases (8%) showed amplification of ECT2, seven (8%) for EIF5A2, nine (11%) for PIK3CA, and eight (10%) for TNFSF10. IAD, invasive adenocarcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317802&req=5

fig01: (a) Amplification of seven selected genes was examined using 15 adenocarcinomas in situ (AIS; Type A or B; blue dot) and 17 early-invasive adenocarcinomas (eIAD; Type D or E; red dot) by quantitative real-time genomic PCR. The ECT2, EIF5A2, PIK3CA, and TNFSF10 genes showed no amplification in AIS (blue arrows). (b) Quantitative real-time genomic PCR was carried out for ECT2, EIF5A2, PIK3CA, and TNFSF10 in 83 lung adenocarcinomas. Values in parentheses indicate the number of cases tested for each type of carcinoma. Seven cases (8%) showed amplification of ECT2, seven (8%) for EIF5A2, nine (11%) for PIK3CA, and eight (10%) for TNFSF10. IAD, invasive adenocarcinoma.
Mentions: The seven selected gene amplifications were examined using 15 AIS (Type A or B) and 17 early-invasive adenocarcinomas (Type D or E) by qPCR (Fig. 1a). All seven genes showed amplification in early-invasive adenocarcinomas, confirming the results of Cancer Array-800. However, several cases of AIS showed amplification of EVI1, SKIL, and MUC4. In contrast, ECT2, EIF5A2, PIK3CA, and TNFSF10 showed no amplification in AIS. Additionally, 51 advanced lung adenocarcinomas, giving a total of 83 adenocarcinomas, were also examined by qPCR. Altogether, seven cases (8%) were amplified at ECT2, seven (8%) at EIF5A2, nine (11%) at PIK3CA, and eight (10%) at TNFSF10 (Fig. 1b).

Bottom Line: Array-comparative genomic hybridization indicated frequent amplification at chromosome 3q26.These results were verified using another set of early-stage adenocarcinomas resected at another hospital.Abnormality of the ECT2 gene occurs at a relatively early stage of lung adenocarcinogenesis and would be applicable as a new biomarker for prognostication of patients with lung adenocarcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.

Show MeSH
Related in: MedlinePlus